DexCom, Inc. DXCM announced that its latest G7 continuous glucose monitoring (CGM) system can now connect with Tandem Diabetes Care's t:slim X2 insulin pump featuring Control-IQ technology. This ...
DexCom (NasdaqGS:DXCM) has begun a broad U.S. rollout of its G7 15-day continuous glucose monitoring system, extending sensor wear time for users. The company is preparing a nationwide release of ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA has granted clearance to a next-generation ...
New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Dexcom, Inc. (NASDAQ: DXCM), a global ...
With more than 10 years of pioneering CGM market leadership in AID integration, Dexcom is the most studied CGM brand with AID capabilities and the clear choice for powering AID systems 3,4 The ...
It takes two: After making its commercial debut early this year, Dexcom’s latest continuous glucose monitor is wrapping up 2023 by connecting with its first automated insulin pump partner, courtesy of ...
SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, commends the expansion of CGM Medicare coverage to ...
The Dexcom G7 continuous glucose monitor (CGM) will now last 15 days, up from the previous 10-day version. The US Food and Drug Administration’s clearance of the extended-wear Dexcom G7 device for ...
Dexcom has received approval from the FDA for a new version of its smartphone connected Dexcom Share platform that will eliminate the docking cradle and allow a patient's continuous glucose monitor ...
Medical Device Network on MSN
Dexcom reports 2025 revenues of $4.66bn yet 2026 outlook lags analyst expectations
Dexcom's 2026 revenue estimates lagged analysts' expectations, according to data compiled by the London Stock Exchange Group ...
New Ontario Drug Benefit (ODB) coverage means eligible Ontarians who take insulin can now benefit from using Dexcom G7 to simplify management of their diabetes. Ontario residents eligible for ODB and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results